Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study.

Authors:
Yin L; Liu KC; Lv WF; Lu D; Tan YL and 4 more

Journal:
Cancer Imaging

Publication Year: 2023

DOI:
10.1186/s40644-023-00574-7

PMCID:
PMC10230673

PMID:
37254146

Journal Information

Full Title: Cancer Imaging

Abbreviation: Cancer Imaging

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Diagnostic Imaging

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateEthics committee approval was received from The First Affiliated Hospital of USTC for a waiver of patient consent (NO.2021-RF-114). Consent for publicationNot applicable. Competing interestsNil. Competing interests Nil."

Evidence found in paper:

"Funding This study was supported by the Fundamental Research Funds for the Central Universities (NO.WK9110000061)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025